Journal Information
Vol. 45. Issue 12.
Pages 611-616 (December 2009)
Share
Share
Download PDF
More article options
Vol. 45. Issue 12.
Pages 611-616 (December 2009)
Special article
Full text access
Strategies for Reducing Risks in Smoking: Opportunity or Threat?
Estrategias de reducción de riesgos en tabaquismo: ¿oportunidad o amenaza?
Visits
4403
Rodrigo Córdobaa, Isabel Nerínb,
Corresponding author
isabelne@unizar.es

Corresponding author.
a Medicina Familiar y Comunitaria, Centro de Salud Delicias Sur, Departamento de Medicina y Psiquiatría, Facultad de Medicina, Universidad de Zaragoza, Zaragoza, Spain
b Unidad de Tabaquismo FMZ, Facultad de Medicina, Universidad de Zaragoza, Zaragoza, Spain
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics
Abstract

The smoking control policies recommended by the World Health Organisation have achieved a slight decrease in smoking prevalence in developed countries, although associated mortality is still very high. The use of tobacco products other than cigarettes and even medicinal nicotine (known as nicotine replacement therapy [NRT]) has been proposed as a risk reduction strategy. Among the tobacco products with less individual risk than cigarettes would be any type of tobacco without smoke (smokeless) with a low content in nitrosamines and modified cigarettes; both forms included under the PREP (Potentially Reduced Exposure Products) concept. The idea would be to promote these products among patients who cannot quit smoking or wish to reduce their risk without giving up nicotine intake. The possible effects of risk reduction strategies, including PREP, on the decreased prevalence and morbidity and mortality are reviewed, and the possible implications that this measure could have in Spain are analysed. Tobacco control measures in Spain have only been made recently and are still insufficient. Therefore, the current priority in Spain is to develop control policies that have proven to be more than effective. The marketing and advertising of new tobacco products, even with reduced potential risk, seems more a serious threat than an opportunity for developing smoking control policies.

Keywords:
Smoking
Risk reduction
Strategies
Resumen

Las políticas de control del tabaquismo recomendadas por la Organización Mundial de la Salud han logrado un discreto descenso en la prevalencia de tabaquismo en los países desarrollados, aunque la mortalidad relacionada sigue siendo muy elevada. Se ha propuesto como estrategia de reducción de riesgos el uso de productos de tabaco distintos a los cigarrillos o bien la nicotina medicinal (conocida como terapia sustitutiva de nicotina o TSN). Entre los productos del tabaco con menos riesgo individual que los cigarrillos estarían algunos tipos de tabaco sin humo (smokeless) con bajo contenido en nitrosaminas y los cigarrillos modificados; ambas formas englobadas bajo el concepto de PREP (Potentially Reduced Exposure Products). La idea sería promover estos productos entre aquellos que no pueden dejar de fumar o bien desean reducir su riesgo sin abandonar el consumo de nicotina. Se revisan los posibles efectos sobre la disminución de la prevalencia y sobre la morbimortalidad de las estrategias de reducción de riesgos, incluyendo los PREP, y se analizan las posibles implicaciones que esta medida podría tener en nuestro entorno. En España, las medidas de control del tabaquismo son recientes y todavía insuficientes. Actualmente, la prioridad en España es, por tanto, el desarrollo de políticas de control que han mostrado su eficacia de forma sobrada. La comercialización y difusión de nuevos productos de tabaco, aún de riesgo potencial reducido, parece más una seria amenaza que una oportunidad para el desarrollo de las políticas de control del tabaquismo.

Palabras clave:
Tabaquismo
Reducción de riesgos
Estrategias
Full text is only aviable in PDF
References
[1.]
Organización Mundial de la Salud.
Diez datos sobre la epidemia de tabaquismo y el control mundial del tabaco.
OMS; febrero de, (2008),
[2.]
Anónimo.
Adding harm reduction to tobacco control [editorial].
[3.]
Socidrogalcohol. Guía sobre reducción de daños. Disponible en http://socidrogalcohol.psiquiatria.com/enlaces/
[4.]
M.R. Law, N.J. Wald.
Environmental tobacco smoke and ischemic heart disease.
Prog Cardiovasc Dis, 46 (2003), pp. 31-38
[5.]
N.S. Godtfredsen, C. Holst, E. Prescott, J. Vestbo, M. Osler.
Smoking reduction, smoking cessation, and mortality: a 16-year follow-up of 19,732 men and women from the Copenhagen Centre for prospective population studies.
Am J Epidemiol, 156 (2002), pp. 994-1001
[6.]
A. Tverdal, K. Bjartveit.
Health consequences of reduced daily cigarette consumption.
Tob Control, 15 (2006), pp. 472-480
[7.]
C. Pisinger, N.S. Godtfrensen.
Is there a health benefit of reduction tobacco consumption? A systematic review.
Nicotine Tob Res, 9 (2007), pp. 631-646
[8.]
E. Prescott, H. Scharling, M. Osler, P. Schnohr.
Importance of light smoking and inhalation habits on risk of myocardial infarction and all cause mortality. A 22- year follow up of 12 149 men and women in The Copenhagen City Heart Study.
J Epidemiol Community Health, 56 (2002), pp. 702-706
[9.]
E. Becoña.
Tratamiento psicológico del tabaquismo.
Adicciones, 16 (2004), pp. 237-263
[10.]
K.O. Fagerström.
Can reduced smoking be a way for smokers not interested in quitting to actually quit?.
Respiration, 72 (2005), pp. 216-220
[11.]
L.F. Stead, T. Lancaster.
Interventions to reduce harm from continued tobacco use.
Cochrane Database Syst Rev, (2007),
[12.]
C.A. Jiménez-Ruiz, J.A. Riesco, A. Ramos, M. Barrueco, S. Solano, J.I. De Granda, et al.
Recomendaciones para el tratamiento farmacológico del tabaquismo. Propuesta de financiación.
Arch Bronconeumol, 44 (2008), pp. 213-219
[13.]
National Cancer Institute. Questions about cigar smoking and cancer. 1998. Disponible en: http://www.cancer.gv/cancertopics/factsheet/tobacco/cigars
[14.]
C. Iribarren, I.S. Tekawa, S. Sidney, G.D. Friedman.
Effect of cigar smoking on the risk of cardiovascular disease, chronic obstructive pulmonary disease, and cancer in men.
N Engl J Med, 340 (1999), pp. 1773-1780
[15.]
M.J. Thun, D.M. Burns.
Health impact of “reduced yield” cigarettes: a critical assessment of the epidemiological evidence.
Tob Control, 10 (2001), pp. i4-11
[16.]
H.A. Tindle, N.A. Rigotti, R.B. Davis, E.M. Barbeau, I. Kawachi, S. Shiffman.
Cessation among smokers who used “light” cigarettes: results from the 2000 National Health Interview Survey.
Am J Public Health, 96 (2006), pp. 1498-1504
[17.]
Organización Mundial de la Salud.
Convenio Marco de la OMS para el Control del Tabaco.
OMS, (2003),
[18.]
Darrall KG, Figins JA. The blocking of cigarette filter ventilation holes. Laboratory of the Government Chemist Report EH40M007/98. 1998.
[19.]
World Health Organization. The scientific basis of tobacco product regulation. WHO Technical Report series n.° 945. Geneva: WHO; 2007.
[21.]
E.L. Wynder, D. Hoffman.
Tobacco and tobacco smoke.
Semin Oncol, 3 (1976), pp. 5-15
[22.]
American Lung Association. Epidemiology and Statistic Unit Research and Program Services. May 2005. Disponible en: http://www.lungusa.org/atf/cf/%7B7A8D42C2-FCCA-4604-8ADE-7F5D5E762256%7D/ASTHMA1.PDF
[23.]
K.E. Warner.
Tobacco harm reduction: promise and perils.
Nicotine Tob Res, 4 (2004), pp. 61-71
[24.]
J. Foulds, L. Ramstrom, M. Burje, K. Fagerström.
Effect of smokeless tobacco (snus) on smoking and public health in Sweden.
Tob Control, 12 (2003), pp. 349-359
[25.]
L.M. Ramström, J. Foulds.
Role of of snus in initiation and cessation of tobacco smoking in Sweden.
Tob Control, 15 (2006), pp. 210-214
[26.]
C.K. Haddock, M.V. Weg, M. DeBon, R.C. Klesges, G.W. Talcott, H. Lando, et al.
Evidence that smokeless tobacco use is a gateway for smoking initiation in young adult males.
Prev Med, 32 (2001), pp. 262-267
[27.]
S.L. Tomar.
Is use of smokeless tobacco a risk factor for cigarette smoking? The US experience.
Nicotine Tob Res, 5 (2003), pp. 561-569
[28.]
S.L. Tomar.
Snuff and smoking in US men: implications for harm reduction.
Am J Prev Med, 23 (2002), pp. 143-149
[29.]
G.F. Wayne.
Potencial reduced exposure products (PREPs) in industry trial testimony.
Tob Control, 15 (2006), pp. 90-97
[30.]
European Commission. Health & Consumer Protection Directorate-General. Electronic cigarettes ant the EC legislation. Orientation Note. Brussels, 22/05/2008.
[31.]
R.S. Caraballo, L.L. Pederson, N. Gupta.
New tobacco products: do smokers like them?.
Tob Control, 15 (2006), pp. 39-44
[32.]
S. Shiffman, J.L. Pillitteri, S.L. Burton, M.E. Di Marino.
Smoker and ex-smoker reactions to cigarettes claiming reduce risk.
Tob Control, 13 (2004), pp. 78-84
[33.]
A. McNeil.
ABC of smoking cessation. Harm reduction.
[34.]
Stratton K, Shetty P, Wallace R, Bondurant S, editors. Clearing the smoke: assessing the science base for tobacco harm reduction. The National Academy Press, 2001. Disponible en: http://www.nap.edu/catalog/10029.html
[35.]
Champan S. Dead customers are unprofitable customers: potential and pitfalls in harm reduction and product regulation. En: Public Health Advocacy and Tobacco Control, editor. Making smoking history. Oxford: Blackwell Publishing; 2007.
[36.]
G. Gómez, M. Barrueco, I. Aparicio, J.A. Maderuelo, M. Torrecilla.
Programa de prevención del tabaquismo en alumnos de enseñanza secundaria.
Arch Bronconeumol, 45 (2009), pp. 16-23
[37.]
M. Barrueco, G. Gómez, M. Torrecilla, A. Pérez, C. Bartolomé.
Valor de la intervención breve y los tratamientos para dejar de fumar en adolescentes.
Arch Bronconeumol, 43 (2007), pp. 334-339
[38.]
J. Britton, R. Edwards.
Tobacco smoking, harm reduction, and nicotine product regulation.
[39.]
S.L. Tomar.
Epidemiologic perspectives on smokeless tobacco marketing and population harm.
Am J Prev Med, 33 (2007), pp. 387-397
[40.]
European Comission. Health & Consumer Protection Directorate-General. Health. Scientific Commitee. Effects of smokeless tobacco Products. Brussels, February 2008.
[41.]
Directiva 2001/37/CE del Parlamento Europeo y del Consejo, de 5 de junio de 2001, relativa a la aproximación de las disposiciones legales, reglamentarias y administrativas de los Estados miembros en materia de fabricación, presentación y venta de los productos del tabaco.
[42.]
International Smokeless Tobacco Company Submission in relation to directive 2001/37/EC to the European Commission. 2004. Disponible en: http://www.ussmokeless.com/regulatory/31.pdf
[43.]
WHO Report on the Global Tobacco Epidemic, 2008. The MPOWE Package. Geneve: WHO; 2008.
[44.]
European Commission. Special Eurobarometer. Attitudes of Europeans towards tobacco. May 2007. Disponible en: http://ec.europa.eu/health/ph_determinants/life_style/Tobacco/Documents/ebs272c_en.pdf
[45.]
M. Barrueco Ferrero, M. Torrecilla García, M.A. Hernández Mezquita, C.A. Jiménez Ruiz, A. Morales Sánchez, A. Alonso Díaz, et al.
Deshabituación tabáquica. Valor del resultado en la fase de acción sobre el resultado en la fase de consolidación.
Arch Bronconeumol, 43 (2007), pp. 136-142
[46.]
M. Trapero-Bertrán.
Evaluación económica de las intervenciones antitabáquicas: ¿nos dejamos algo en el tintero?.
Arch Bronconeumol, 45 (2009), pp. 209-211
[47.]
P.A. McDaniel, E.A. Smith, R.E. Malone.
Philip Morris Project sunrise: weakening tobacco control by working with it.
Tob Control, 15 (2006), pp. 215-230
[48.]
J. Pierce, M. Leon, On behalf IARC Handbook and IARC Secretariat.
Special Report: Policy. Effectiveness of smoke-free policies.
Lancet Oncol, 9 (2008), pp. 614-615
Copyright © 2009. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?